Last reviewed · How we verify
NCT03715036
Point of Care Ultrasound Screening for Abnormal Fetal Growth During Routine Antenatal Visits
NA trial testing Point-of-care US in Prenatal Disorder in 177 participants. Completed in 30 March 2020.
30 March 2020
Quick facts
| Lead sponsor | The University of Texas Medical Branch, Galveston |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 177 |
| Start date | 29 April 2019 |
| Primary completion | 30 March 2020 |
| Estimated completion | 30 March 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Point-of-care US
Conditions studied
- Prenatal Disorder — all drugs for Prenatal Disorder →
Sponsor
The University of Texas Medical Branch, Galveston
Who can join
18 and older, female only, with Prenatal Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Abdominal circumference (AC) in the fetus is the single most useful indicator of fetal growth abnormalities. Measurement of AC as well as DVP do not require extensive training. Our objective is to evaluate if introduction of bedside ultrasound during routine antenatal visits to evaluate fetal AC and amniotic fluid DVP would decrease the false positive rates of fundal height measurement in diagnosing intrauterine growth abnormalities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03715036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prenatal Disorder
Currently open trials in the same condition.
- NCT06382636 — Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes · NA · recruiting
- NCT03831256 — PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood · NA · active not recruiting
Other The University of Texas Medical Branch, Galveston trials
Trials by the same sponsor.
- NCT04095260 — Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes. · not yet recruiting
- NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
- NCT07337915 — Improving Sleep In Midlife Women · NA · recruiting
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT07087743 — Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03715036 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03715036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing